Merck KGaA, Darmstadt, Germany, to Sell Consumer Health to Procter & Gamble
- Next step in the strategic focus on innovation driven businesses of Merck KGaA, Darmstadt, Germany
- All-cash purchase price of € 3.4 billion
- Proceeds will support further deleveraging and increase flexibility to strengthen all three business sectors
Darmstadt, Germany, April 19, 2018 – Merck KGaA, Darmstadt, Germany, announced today that it has signed an agreement to sell its global Consumer Health business to Procter & Gamble (P&G) for approximately € 3.4 billion in cash, or approximately $ 4.2 billion at current exchange rates. The transaction, which is expected to close by the end of the fourth quarter 2018, is subject to regulatory approvals and satisfaction of certain other customary closing conditions. Merck KGaA, Darmstadt, Germany, intends to use the net proceeds from the divestiture primarily to accelerate deleveraging. At the same time, it will allow Merck KGaA, Darmstadt, Germany, to increase flexibility to strengthen all three business sectors.
“The divestment of the Consumer Health business is an important step in our strategic focus on innovation driven businesses within Healthcare, Life Science and Performance Materials. It is a clear demonstration of our continued commitment to actively shape our portfolio as a leading science and technology company. The attractive price reflects the high asset value and the performance Consumer Health has delivered,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. “Consumer Health is a strong business that deserves the best possible opportunities for its future development. With P&G we have found a strong, highly recognized player who has the necessary scale to successfully drive the business going forward.”
“P&G’s global scale and strategic interest in the health and well-being of consumers provide an excellent basis for accelerating growth, leveraging our teams’ capabilities and expanding the Consumer Health business profitably. The marketed portfolios, product pipelines and geographic footprints of both businesses are highly complementary,” said Belén Garijo, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Healthcare. “With this transaction, we continue to rigorously deliver on our strategy to become a global specialty innovator and bring breakthrough medicines to patients.”
“We like the steady, broad-based growth of the OTC healthcare market and are pleased to add the Consumer Health portfolio and people of Merck KGaA, Darmstadt, Germany, to the P&G family,” said David Taylor, P&G Chairman of the Board, President and CEO.
“These leading brands and the great employees of the Consumer Health business of Merck KGaA, Darmstadt, Germany, will complement our Personal Health Care business very well,” said Tom Finn, President, P&G Global Personal Health Care. “This acquisition helps us continue to drive sales and profit growth for P&G by providing the capabilities and portfolio scale we need to operate a winning global OTC business.”
Between 2015 and 2017, net sales of the Consumer Health business of Merck KGaA, Darmstadt, Germany, grew organically by 6%, outpacing the consumer health market’s growth of approximately 4% over the same period. For the full year 2017, net sales of the Consumer Health business of Merck KGaA, Darmstadt, Germany, amounted to € 911 million.
The transaction will be executed through the sale of shares in a number of legal entities as well as various asset sales of Merck KGaA, Darmstadt, Germany, and comprises the Consumer Health business across 44 countries, including more than 900 products and two Consumer Health-managed production sites in Spittal (Austria) and Goa (India). As part of the transaction, it is contemplated that approximately 3,300 employees, mainly from the Consumer Health business of Merck KGaA, Darmstadt, Germany, will transition to P&G upon completion of the transaction, subject to prior works council consultation where required. This includes Merck KGaA, Darmstadt, Germany, employees who, through their work, are fully dedicated to Consumer Health, and employees in share deal entities. The sale of the global Consumer Health business of Merck KGaA, Darmstadt, Germany, does not yet comprise the French Consumer Health business, where P&G has made a binding offer to acquire the shares and assets upon Merck KGaA, Darmstadt, Germany, having informed and consulted with the relevant works council representatives. For the Indian business, it has been agreed that P&G will acquire the majority shareholding of Merck KGaA, Darmstadt, Germany, in Merck Ltd., Mumbai, India, a subsidiary of Merck KGaA, Darmstadt, Germany, a publicly traded company, and subsequently make a mandatory tender offer to minority shareholders. As part of the transaction, Merck KGaA, Darmstadt, Germany, and P&G have agreed a number of manufacturing, supply and service agreements.
In September 2017 Merck KGaA, Darmstadt, Germany, announced that it was preparing strategic options for its Consumer Health business, including a potential full or partial sale of the business as well as strategic partnerships.
J.P. Morgan acted as financial adviser to Merck KGaA, Darmstadt, Germany, on the transaction, and Freshfields Bruckhaus Deringer acted as a legal adviser to Merck KGaA, Darmstadt, Germany.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting.